Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Cetrelimab (Primary) ; Niraparib (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms QUEST
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Dec 2018 Planned number of patients changed from 60 to 150.
    • 27 Dec 2018 Planned End Date changed from 31 Dec 2020 to 31 Aug 2021.
    • 08 Nov 2018 Planned End Date changed from 31 Mar 2021 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top